VIRACEPT

Compare VIRACEPT  to:
Compare
Compare

Generic Name for VIRACEPT

Nelfinavir (as mesylate) 250mg, 625mg; tabs.

Legal Classification:

Rx

Pharmacological Class for VIRACEPT

HIV-1 protease inhibitor.

Manufacturer of VIRACEPT

Agouron Pharmaceuticals

Indications for VIRACEPT

HIV infection.

Adults and Children:

Take with food. May dissolve tab and mix in small amount of water; powder may be mixed with a small amount of non-acidic food or beverage. <2yrs: not recommended. 2–13yrs: 20–30mg/kg 3 times daily; max 750mg 3 times daily. >13yrs: 1.25g twice daily or 750mg 3 times daily. Reduce concomitant rifabutin dose by ½ and give nelfinavir 1.25g twice daily.

Also:

Contraindications for VIRACEPT

CYP3A substrates that may cause serious events if blood levels are elevated (eg, cisapride, pimozide, midazolam, triazolam, lovastatin, simvastatin, ergots, amiodarone, quinidine).

Warnings/Precautions for VIRACEPT

Hepatic impairment. Diabetes. Monitor for hyperglycemia or fat redistribution, hemophiliacs for spontaneous bleeding. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for VIRACEPT

See Contraindications. Rifampin, St. John's wort: not recommended. Potentiates CYP3A substrates (eg, dihydropyridine calcium channel blockers, cyclosporine, tacrolimus, sirolimus, rifabutin, atorvastatin), sildenafil (max 25mg in 48 hours), phenytoin (monitor). Nelfinavir levels decreased by CYP3A inducers (eg, phenytoin, rifampin, carbamazepine, phenobarbital) or CYP2C19 inducers. Nelfinavir levels increased by CYP3A or CYP2C19 inhibitors. Antagonizes methadone, oral contraceptives (use additional or alternative contraception). Indinavir, ritonavir, saquinavir increase nelfinavir levels. Concomitant azithromycin: monitor for azithromycin toxicity (eg, elevated liver enzymes). Others: see literature.

Adverse Reactions for VIRACEPT

Diarrhea, nausea, flatulence, abdominal pain, rash, redistribution of body fat, diabetes, hyperglycemia.

Notes for VIRACEPT

Register pregnant patients exposed to nelfinavir by calling (800) 258-4263.

How is VIRACEPT supplied?

Tabs 250mg—270, 300
625mg—120
Oral Pwd—144g

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions